Dataset opportunity
Sniclinic — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Sniclinic, usable for Diagnostic AI and Computer Vision.
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI-Powered Diagnostic Imaging market was valued at $3.46 billion in 2024, with a projected CAGR of 26.40% (2025-2032) (source: Polaris Market Research). [1]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Sniclinic holds a substantial Medical Imaging Dataset, comprised of various image modalities and supported by industrial data, medical records, and regulatory evidence. This curated collection is specifically structured for developing, training, and validating high-performance Diagnostic AI algorithms, enabling breakthroughs in automated disease detection and analysis based on proprietary observational research and potentially primary clinical trial data.
The global AI-powered diagnostic imaging market represents a significant opportunity, valued at $3.46 billion in 2024 and projected to expand at a remarkable CAGR of 26.40%. [1] While access to this valuable data requires navigating stringent client confidentiality agreements and high regulatory compliance for medical_records (e.g., GDPR), the immense market growth signals a compelling return on investment for AI buyers capable of securing these high-quality assets. ⚠ Diligence (valuable data, access to negotiate): Primary clinical trial data is likely subject to strict client confidentiality and ownership; Medical and health-related data requires high regulatory compliance (GDPR/PDPA); Proprietary observational research and survey datasets may be more accessible than interventional trial data · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Evidence confirms Sniclinic possesses a proprietary medical imaging dataset derived from its clinical research operations. This asset is a direct fit for companies developing diagnostic AI, a market projected to grow at a 26.40% CAGR. The data's origin in observational research and clinical trials suggests a high-value, structured collection ideal for training and validating next-generation medical device algorithms.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is extremely high, driven by the explosive growth of the AI-powered diagnostic imaging market, which is expanding at a CAGR of 26.40%. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
surplus=medium — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ review — Sniclinic is a Contract Research Organization (CRO) whose core business is designing and executing clinical trials for other companies, not selling a product from which data is a by-product. Issues: Company's core business is providing clinical research services, data management, and statistical analysis for hire. [3, 7, 11]; They are a service provider (a data processor/generator for others), not a primary data holder with 'dormant' data. [1, 5]; The data generated is to 'validate he
- Deep Qualification90
⚠ needs review — Sniclinic is a Contract Research Organization (CRO) that provides clinical trial services for clients; it does not own the resulting data, which belongs to the trial sponsors, making the acquisition of a proprietary dataset from them unlikely. [data is owned by the company's customers; licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence points to a collection of medical images gathered through observational research, providing the real-world visual data essential for training robust diagnostic AI models.
Regulatory records
The holder's expertise in clinical trial reporting indicates the dataset is likely well-documented and structured, a critical factor for AI developers seeking data for regulatory submission.
Industrial data
This confirms the holder's operational focus on the medical devices sector, ensuring the dataset's context and format are directly relevant to companies developing commercial diagnostic imaging solutions.
Deal room
Deal Room — Sniclinic — Medical Imaging Dataset Opportunity
Medical Imaging Dataset (Image, healthcare). Best AI use-case: Diagnostic AI. Target buyers: Medical-AI & diagnostic-imaging companies. Market: Global AI-Powered Diagnostic Imaging market was valued at $3.46 billion in 2024, with a projected CAGR of 26.40% (2025-2032) (source: Polaris Market Research). [1]. Rarity: High (proprietary); accessibility: Restricted. Key risk: Mixed ownership — GDPR-sensitive (PII review). Recommended deal structure: Data Sharing Agreement. Investment score 45.0/100.
Buyer persona
Medical-AI & diagnostic-imaging companies
The type of company or team most likely to buy or use this dataset — the target on the demand side.Market
Global AI-Powered Diagnostic Imaging market was valued at $3.46 billion in 2024, with a projected CAGR of 26.40% (2025-2032) (source: Polaris Market Research). [1]
A rough read on demand and price band for this data, from market signals ($ = niche, $$$ = high AI-buyer demand).Risk
Mixed ownership — GDPR-sensitive (PII review)
The main legal and compliance constraints on using or transferring this data — PII/GDPR, licensing rights, regulatory limits.Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Coverage
Scanned sources
Deliverable
Premium dataset report
Sniclinic Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global artificial intelligence in diagnostics market = $1.5 billion in 2024, CAGR 21.5% (source: Global Market Insights Inc.). Investment score 47.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.